IFP Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

IFP Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-300	Closed	-$1.29K	–	3110
2019 Q4	$2K	Hold	300	–	–	﹤0.01%	2579
2019 Q3	$2K	Buy	+300	New	+$1.5K	﹤0.01%	2768
2019 Q1	–	Sell	-341	Closed	-$1K	–	3773
2018 Q4	$1K	Hold	341	–	–	﹤0.01%	3456
2018 Q3	$2K	Hold	341	–	–	﹤0.01%	3620
2018 Q2	$3K	Hold	341	–	–	﹤0.01%	3531
2018 Q1	$2K	Hold	341	–	–	﹤0.01%	3578
2017 Q4	$2K	Sell	341 -110	-24%	-$668	﹤0.01%	3629
2017 Q3	$3K	Hold	451	–	–	﹤0.01%	3675
2017 Q2	$3K	Hold	451	–	–	﹤0.01%	3665
2017 Q1	$4K	Hold	451	–	–	﹤0.01%	3465
2016 Q4	$4K	Buy	451 +41	+10%	+$303	﹤0.01%	3447
2016 Q3	$3K	Hold	410	–	–	﹤0.01%	3507
2016 Q2	$2K	Buy	+410	New	+$1.98K	﹤0.01%	3538
2016 Q1	–	Sell	-410	Closed	-$3K	–	3761
2015 Q4	$3K	Buy	+410	New	+$2.69K	﹤0.01%	3251

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

IFP Advisors's PGNX Position: Q1 2020 in Review

IFP Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 300 shares — an estimated $1.29K sold.

IFP Advisors first reported a position in PGNX in Q4 2015 and held it in 14 quarters. The position peaked at $4K in Q1 2017. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

IFP Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
IFP Advisors sold 300 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $1.29K.
IFP Advisors first reported a position in Progenics Pharmaceuticals Inc in Q4 2015 and held it in 14 quarters.
IFP Advisors's Progenics Pharmaceuticals Inc position peaked at $4K in Q1 2017.
129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on IFP Advisors's 13F filing for Q1 2020, filed 12 May 2020.